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Background: Mechanisms of maintenance of atrial ﬁbrillation are known to include ﬁbrosis. Galectin-3, as a
biomarker of ﬁbrosis, may be a valuable marker of atrial remodeling. We sought to ﬁnd whether there was a
link between clinical features and higher galectin-3 levels in patients with atrial ﬁbrillation.
Methods: Serum concentrations of Galectin-3 were determined in a consecutive series of patients addressed for
ablation of atrial ﬁbrillation.
Results: One-hundred-and-eighty-seven patients were included, 56% having a paroxysmal type of atrial ﬁbrilla-
tion. Mean Galectin-3 concentration was 14.5 ± 5.5 ng/mL. Age, persistent form of atrial ﬁbrillation, underlying
cardiac disease, heart failure, decreased left ventricular ejection fraction (LVEF), hypertension, diabetes, treat-
ment with ACEI/ARB, enlarged left atrium and renal insufﬁciency were associated with higher Galectin-3 levels.
Importantly, persistent form of atrial ﬁbrillation, female sex, and LVEF b45% were independent predictors
(OR 13.9, p = 0.01, OR = 11.7, p = 0.03, and OR 54.2, p = 0.04, respectively) of higher Galectin-3 levels
(≥15 ng/mL).
Conclusions: Persistent type of atrial ﬁbrillation is an independent predictor of higher Galectin-3 concentration.
This biomarker ofﬁbrosismay be implied in themechanismsof atrial remodeling andmaintenance of atrialﬁbril-
lation, and thus be helpful for the design of therapeutic strategy in patients with atrial ﬁbrillation.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Atrial ﬁbrillation, characterized by rapid and irregular electrical ac-
tivity within the atria, is associated with an increased risk of thrombo-
embolic events, hospitalizations for heart failure, and overall mortality
[1]. The natural history of the disease has several presentations and
evolutions. Primary AF typically begins with paroxysmal episodes of
arrhythmia, which by arbitrary deﬁnition last less than seven days and
self-terminate spontaneously. It then may evolve towards so-called
persistent AF, deﬁned by more prolonged episodes lasting more than
seven days and/or necessitatingpharmacological or electrical cardiover-
sion. AFwith over than one year of continuous arrhythmia deﬁnes long-
lasting or long-term persistent AF. Finally, the term permanent should
be used whenever treatment refractory persistent AF is observed [2].onance imaging; LVEF, left ven-
F, heart failure; BMI, bodymass
angiotensin converting enzyme
larﬁltration rate.
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and Ltd. This is an open access articlePatients may evolve very differently. Some patients will present
persistent AF as a ﬁrst manifestation of the disease, while some will
pass through several years of paroxysmal episodes. Although themech-
anisms involved in the evolution of the disease remain unclear, AF has
been shown to lead to electrical remodeling and progressive ﬁbrosis of
the atria, which in turn favor AF perpetuation and chronicization: "AF
begets AF" [3,4].
Evaluation of the ﬁbrosis extent is thus important in order to assess
the prognosis of the disease, and may be useful for choosing the most
adapted therapeutic strategy. Indeed, strategies for AF ablation may
differ according to the amount of diseased tissue, froma simple isolation
of the pulmonary veins to an extensive ablation of both atria [5]. The
speciﬁc efﬁcacy of the different strategies also differs signiﬁcantly,
with extensive atrial ﬁbrosis being associated to a poorer outcome
after ablation of AF [6]. Accordingly, it has been proposed to use some
antiﬁbrotic agents in patients with AF [7,8].
Since the atrial wall is thin, evaluation of ﬁbrosis within the atria
remains difﬁcult. While some authors have proposed to perform MRI,
this technique could be difﬁcult to access routinely [9].
Galectin-3 (Gal-3) is a member of the ß-galactoside-binding lectins
family. Gal-3 has a pleiotropic distribution and could be found in the
cytoplasm, in the nucleus and at the cell membrane or as a pentameric
circulating form [3]. Gal-3 is highly expressed in ﬁbrotic tissues, andunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Baseline characteristics for all patients.
TOTAL (N = 187)
Male (%) 127 (68)
Age (years) 62 ± 10
BMI (kg/m2) 29 ± 6
Paroxysmal AF (%) 105 (56)
Lone AF (%) 62 (33)
Structural Heart Disease 46 (25)
Heart Failure (%) 45 (24)
Hypertension (%) 94 (50)
Diabetes Mellitus (%) 34 (18)
TIA or Stroke (%) 7 (4)
Vascular Atherosclerosis (%) 16 (9)
CHADS2 Score 1.43 ± 1.15
CHA2DS2−VASC Score 1.90 ± 1.47
ACE/ARB N (%) 36 (19)
Betablocker N (%) 62 (56)
Antiarrhythmic Drugs Class I/III N (%) ⁎ 106 (57)/144 (77)
LA Diameter (mm) 42 ± 7
Index LA Volume (mL/m2) 66 ± 19
LVEF (%) 54 ± 11
MDRD GFR (mL/min/1.73 m2) 74 ± 20
hs-CRP (mg/L) 5.0 ± 8.5
BNP (ng/L) 156 ± 253
Galectin-3 (ng/mL) 14.5 ± 5.5
QRS width (ms) 96 ± 20
Sinus rhythm at admission (%) 109 (58)
⁎ Antiarrhythmic drugs (≥1) prescribed before ablation.
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human [10–12]. It is mainly produced by activated macrophages,
mast cells and eosinophils, and plays a role in cell adhesion and
proliferation, increasing ﬁbrosis. However, the respective mecha-
nisms by which Gal-3 exerts ﬁbrogenic activity are not completely
depicted. Extracellular pentameric Gal-3 interaction with proﬁbrotic
effectors such as TGF-β1 could be a part of the pathway that initiates
ﬁbrogenesis. Gal-3 has a pivotal role in cardiac ﬁbrosis [12]. Mammalian
models of cardiac ﬁbrosis demonstrate high level of Gal-3. Accord-
ingly, it has been shown that Gal-3 inhibition prevents cardiac
ﬁbrosis [13].
Recently, Gal-3 has been suspected to play a role in promoting ﬁbrosis
within atria in patients with AF [3]. Gal-3 levels correlate with risk factors
of cardiovascular disease such as hypertension, diabetes or obesity, and
were shown elevated in heart failure [14]. For these patients, Gal-3 has
been proposed as a biomarker to estimate their prognosis [15].
We thus hypothesized that a high level of Gal-3 could be primarily
observed in patients with a persistent form of AF, who are prone to
more extensive atrial ﬁbrosis.Table 2
Characteristics of patients according to quartiles of Galectin-3 (ng/mL).
Q1 b 10.8 Q2 10.8-13.4
Galectin-3 (ng/mL) 8.9 ± 1.2 12.0 ± 0.7
Male Gender (%) 79 79
Age (years) 58 ± 11 62 ± 8
BMI (kg/m2) 26 ± 3 29 ± 6
Paroxysmal AF (%) 79 55
Structural Heart Disease (%) 19 19
Heart Failure (%) 9 12
Hypertension (%) 33 50
Diabetes Mellitus (%) 5 14
LA Diameter (mm) 40 ± 7 40 ± 6
Index LA Volume (ml/m2) 62 ± 21 61 ± 15
LVEF (%) 57 ± 9 57 ± 8
MDRD GFR (ml/min/1.73 m2) 81 ± 17 80 ± 23
hs-CRP (mg/L) 4.4 ± 7.3 3.3 ± 3.9
BNP (ng/L) 86 ± 111 103 ± 1942. Materials and Methods
2.1. Inclusion
Consecutive patients with symptomatic AF referred to our depart-
ment for ablation during the year 2013 were included in this study.
Exclusion criteria included all non-cardiac conditions with expected
elevated Gal-3 levels, such as liver cirrhosis, pancreatitis or chronic
inﬂammatory disease. Patients with a history of ablation procedure for
AF were also excluded. Collected clinical data included symptoms
(EHRA classiﬁcation) and history of arrhythmia, presence of thrombo-
embolic risk factors (according to CHADS2 and CHA2DS2-VaSC scores),
and past and current medications. Trans-thoracic echocardiography
and cardiac magnetic resonance imaging were performed to assess left
ventricular function and left atrial diameter and volume.
The local ethics committee for human research approved the study
protocol. All patients signed informed consent before inclusion.
2.2. Galectin-3
During the early stage of AF ablation procedure, blood samples were
collected through the femoral vein sheath in order to determine the
anticoagulation time. Dosage of serum level of Gal-3 was performed
on the residual sample.
Determination of Gal-3 level was prospectively completed using the
VIDAS Galectin-3 kit (bioMérieux, Marcy-l'Etoile, France). VIDAS
Galectin-3 is an automated quantitative test. The kit measuring range
is 3.3-100 ng/mL. The assay principle is a one-step immunoassay
sandwich method with ﬁnal ﬂuorescent detection.
2.3. Statistical analyses
Analyses were performed using JMP version 9 (SAS Institute Inc.,
Cary, NC, USA). Numeric datawere expressed asmean± standard devi-
ation (95% conﬁdence interval). Student T-test and Chi-2 were per-
formed for comparison between groups. A nominal logistic regression
model was used to assess the factors independently associated with
signiﬁcantly higher Gal-3 levels (above the mean value). Main
confounding factors were tested in univariate analysis, and parameters
associated with elevated Gal-3 levels (p b0.10) were used for analyses
in the multivariate model. A p-value b0.05 was considered signiﬁcant.
3. Results
3.1. Population
One-hundred-and-eighty-seven patients met the criteria for inclu-
sion in the study. Patients were predominantly men with a mean ageQ3 13.5-17.3 Q4 N 17.3 p
15.1 ± 1.1 21.9 ± 4.8 b0.0001
60 64 0.12
64 ± 9 66 ± 10 0.004






45 ± 9 43 ± 7 0.006
69 ± 18 72 ± 19 0.04
52 ± 12 49 ± 12 0.005
75 ± 16 64 ± 20 0.0001
4.1 ± 3.5 8.5 ± 14.1 0.01
214 ± 278 245 ± 368 0.0005
Table 3






Age ≥65 years 3.09 (1.62-5.90) 0.0005 2.86 (0.46-21.5) 0.26
Sex: female 1.85 (0.94-3.62) 0.07 11.7 (1.34-100+) 0.03
Type of AF: persistent 3.03 (1.59-5.77) 0.0006 13.9 (1.81-100+) 0.01
Cardiac disease 2.40 (1.17-4.91) 0.02 9.76 (0.45-100+) 0.15
Heart failure 7.62 (3.44-16.9) b0.0001 0.81 (0.03-19.7) 0.90
Hypertension 2.51 (1.32-4.77) 0.004 3.13 (0.38-34.1) 0.29
Diabetes 2.59 (1.16-5.77) 0.02 0.47 (0.04-3.62) 0.48
ACEI or ARB 2.96 (1.39-6.31) 0.004 0.68 (0.06-7.02) 0.74
QRS width ≥120 ms 3.70 (0.80-17.2) 0.09 0.04 (0–1.31) 0.07
LA volume ≥60 mL/m2 2.15 (1.09-4.25) 0.03 0.78 (0.10-5.35) 0.80
LVEF b45% 5.12 (1.99-13.2) 0.0004 54.2 (1.27-100+) 0.04
Renal failure (MDRD b60) 7.35 (3.05-17.7) b0.0001 2.25 (0.19-28.6) 0.51
58 N. Clementy et al. / IJC Metabolic & Endocrine 5 (2014) 56–60of 62±10 years. Hypertensionwas found in 50% of patients, diabetes in
18%, transient ischemic attack or stroke in 4%.Mean LVEFwas 54±11%.
All characteristics of the patients are reported in Table 1.
3.2. Galectin-3 serum levels
Mean Gal-3 level was 14.5 ± 5.5 ng/mL. Quartiles were: b10.8 (Q1),
10.8-13.4 (Q2), 13.5-17.3 (Q3), and N17.3 ng/mL (Q4). Subjects in the
higher quartiles (Q3 and Q4) were more likely to be older, female,
have hypertension, obesity, diabetes, and renal insufﬁciency, present a
history of heart failure, with higher levels of BNP, an enlarged left
atrium, and have persistent AF (Table 2).
3.3. Association between Galectin-3 and baseline characteristics
A Gal-3 level ≥15 ng/mL was considered to be highly elevated.
An age ≥65 years, female sex, persistent form of AF, underlying
cardiac disease, heart failure, decreased LVEF (b45%), hyperten-
sion, diabetes, treatment with ACEI/ARB, enlarged left atrium
(≥60 mL/m2) and renal insufﬁciency (MDRD glomerular ﬁltration
rate b60 mL/min/1.73 m2) were associated with higher Gal-3 levels
(p b 0.10). In the ﬁnal multivariate model, which accounted for 51% of
the total variation of Gal-3 levels in our population (p b 0.0001), the
persistent form of AF was found to be the stronger predictor indepen-
dently associatedwith Gal-3≥ 15 ng/mL (p= 0.01), alongwith female
sex and reduced LVEF (Table 3). We also found Gal-3 levels to be
correlated with CHA2DS2-VaSC score, higher scores being signiﬁcantly
associated with higher serum levels (Fig. 1).Fig. 1. Galectin-3 levels according to the CHA2DS2-VaSC score. From 0 to N5, levels of
Gal-3 are: 11.8 ± 5.1, 12.5 ± 3.8, 16.2 ± 5.3, 15.5 ± 5.0, 15.4 ± 4.9, and 20.9 ±
7.4 ng/mL respectively (p b 0.0001).3.4. Type of AF
Comparison between patients with paroxysmal and persistent AF
showed signiﬁcantly higher Gal-3 levels in the persistent group
(13.1 ± 4.8 versus 16.2 ± 5.8 ng/mL, p = 0.0003) (Fig. 2).
Patients presenting lone AF (n= 41) had lower Gal-3 levels as com-
pared to thosewith AFwith cardiovascular risk factors or HF (12.7±4.8
versus 15.4 ± 5.6 ng/mL, p = 0.002) (Fig. 3).
4. Discussion
4.1. Major Findings
To our knowledge, this is the ﬁrst study to assess Gal-3 serum levels
in patients with AF ablation. This study showed that: (1) Gal-3 levels
were signiﬁcantly higher in the persistent formof AF as compared to pa-
tientswith paroxysmal AF; (2) persistent formof AFwas identiﬁed as an
independent factor associated with higher Gal-3 levels.
4.2. Fibrosis in atrial ﬁbrillation
AF is promoted by structural, electrical or various other abnormali-
ties within the atria, leading to reentry and triggered activity. In early
stage of the disease, the "triggers", focal arrhythmogenic activity, partic-
ularly present within the ostia of the pulmonary veins, may play a dom-
inant role. But with the progression of the disease, the "substrate", atrial
ﬁbrosis, causes a tissue inhomogeneity associated to slow conduction
velocities and short refractory periods, allowing the establishment and
maintenance of arrhythmia [16–19]. Progressive atrial ﬁbrosis is
common in older age, hypertension, diabetes and obesity, which are
all risk factors for atrial ﬁbrillation.
Using appropriate software, MRI identiﬁcation of delayed enhance-
ment remains the gold standard to characterize extend of ﬁbrotic tissue
within the atria. It proved to be helpful to select the appropriate patients
in catheter ablation of AF [20]. However, this technique lacks adapted
availability in regular practice. A second limitation of this technique
relates to its feasibility. In the DECAAF study, estimation of atrial tissue
ﬁbrosis was impossible in 17% of patients because of poor imaging
quality [21]. Finally, MRI would appear a cost ineffective technique
when compared to a serum level of Gal-3. It remains to be conﬁrmed
that Gal-3 concentration allows an efﬁcient selection of patients with
low ﬁbrosis and thus better prognosis after ablation.Fig. 2. Galectin-3 levels according to the type of AF: paroxysmal versus persistent.
Comparison between patients with paroxysmal (n = 105) and persistent (n = 82) AF
showed signiﬁcantly higher Gal-3 levels in the persistent group (13.1 ± 4.8 versus
16.2 ± 5.8 ng/mL, p = 0.0003).
Fig. 3. Galectin-3 levels according to the type of AF: lone AF versus AF associated with
hypertension, diabetes or heart failure (other). Patients presenting lone AF (n = 62)
had lower Gal-3 levels as compared to those with AF with cardiovascular risk factors or
HF (n = 125) (12.7 ± 4.8 versus 15.4 ± 5.6 ng/mL, p = 0.002).
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Although clinical data are still lacking, animal models of cardiac ﬁ-
brosis have been shown to harbor an upregulation of Gal-3. Ho et al.
have shown in a large cohort that higher Gal-3 levels were associated
with increased risk of developing AF in the general population, although
not after accounting for other risk factors [22]. In that study, the mean
value of Gal-3 in patients developing AF was 15.0. In our study, we
used for the ﬁrst time a selected population of patients referred for AF
ablation, in which such markers may have therapeutic implications.
Patients with reduced left ventricular ejection fraction were included,
but to gain speciﬁcity, clinical conditions known to be associated with
elevated Gal-3 levels, such as cirrhosis, pancreatitis, or chronic inﬂam-
matory disease, were excluded. We found that higher Gal-3 levels
(≥15 ng/mL) were present in older patients, female, and those with
hypertension or diabetes. In multivariable analysis, the persistent form
of AF was associated with Gal-3 levels of 15 ng/mL or more, which
may imply that ﬁbrosis plays a role in the maintenance of AF. These
results conﬁrm those of another study by Szadkowska, in a selected
population after a ﬁrstmyocardial infarction [23]. They showed an asso-
ciation between new-onset AF and Gal-3 levels N16 ng/mL.
In our study, an enlarged left atrial volume was not independently
associated with higher gal-3 levels. This is conﬁrmed by the results of
the DECAAF study where left atrial ﬁbrosis quantitatively measured
with MRI was not correlated with an enlarged left atrial volume [21].
As MRI analysis, Gal-3 levels may only reﬂect the degree of ﬁbrosis,
whatever the size of left atrium.
4.4. Limitations
The extent of the cohort is an obvious limitation of this study.
Although it permitted to obtain results with statistical signiﬁcance,
a more representative prospective study is awaited. Patients were
addressed for established AF needing ablation and thus may not reﬂect
the general population presenting AF.We also did not useMRI to assess
real extend of ﬁbrosis within left atrium.
4.5. Perspectives
Gal-3 level might represent a prognostic factor in this population, a
trait that could be established through a prospective study. Gal-3 maypredict the substrate that needs to be treated by radiofrequency
ablation. If proven this would offer a cost effective alternative to MRI.
Patients with paroxysmal AF and higher Gal-3 levels might require ad-
ditional intervention to complete pulmonary vein isolation [24]. Gal-3
level might also be a marker of thromboembolic risk, as it seems to
correlate with CHA2DS2-VaSC score. Lastly, Gal-3 levels may help
guiding the medical therapy, as ACEI, anti-aldosterone or ARB are
known to reduce ﬁbrosis and AF occurrence [25].
5. Conclusions
In patients with AF, the presence of a persistent form of arrhythmia
is an independent predictor of higher levels of galectin-3, a biomarker of
ﬁbrosis, a mechanism implied in atrial remodeling and maintenance of
AF. This novel biomarker might be of considerable interest to deﬁne
the therapeutic strategy for patients experiencing AF.
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